A female scientist sits amid large machinery in a leading research center.

CREDIT: Istock.com/SolStock

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Refeyn earns a place on The Sunday Times 100 Tech list, highlighting strong growth in bioanalytical instrumentation.
| 1 min read
Written byRefeyn
Register for free to listen to this article
Listen with Speechify
0:00
1:00

Oxford, UK – 26 January 2026 – Refeyn, the company behind pioneering mass photometry technology, has been named in The Sunday Times 100 Tech 2026, an annual ranking of the fastest-growing private technology companies in the UK.

The Sunday Times 100 Tech list recognizes companies based on three-year revenue growth, highlighting businesses that have demonstrated sustained commercial momentum and technological impact. Refeyn ranked 39th in the hardware category, reflecting revenue growth of approximately 40 percent over the last three years.

The ranking places Refeyn among a cohort of high-growth UK technology firms spanning sectors including the life sciences, energy and sustainability, telecommunications, and digital technology.

“Being recognized in The Sunday Times 100 Tech list is an important milestone for the company,” said Gerry Mackay, Refeyn’s CEO. “It reflects the impact our technology has had, the trust we have established among our customers, and the dedication of our staff as we continue to build the business.”

“This recognition validates our focus on delivering meaningful value to the scientists using our tools – across academia, contract research and manufacturing, and biopharma,” added Fiona Coats, Refeyn’s Chief Product and Marketing Officer.

Spun out of Oxford University in 2018, Refeyn develops bioanalytical instruments that feature its innovative mass photometry technology. The company works with customers in academia and industry – including in the development and manufacturing of mRNA, cell and gene, and antibody therapeutics. Mass photometry has been widely adopted and has been used or cited in more than 1,400 scientific publications. Refeyn is headquartered in Oxford, UK, with a US headquarters in Waltham, Massachusetts, and additional sites across Europe, Asia and the US.

The Sunday Times 100 Tech recognition follows on Refeyn’s announcement earlier this month that they had been recognized as a Top Employer for 2026 in the UK.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A syringe positioned horizontally above a small vial labeled “cancer vaccine” against a solid purple background.
Rapid DNA-to-mRNA workflows help scientists keep pace with rapidly evolving cancer through personalized vaccines. 
Futuristic 3D human figure surrounded by medical technology and data visuals.
Understand how a human-relevant in vitro model can be used to improve next generation risk assessment (NGRA).
Point-cloud style digital liver illustration with branching vessels on a dark teal background.
Explore the role of microphysiological systems in advancing human-relevant liver toxicity testing and mechanistic evaluation.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue